JCR Pharmaceuticals Co., Ltd. provided earnings guidance for the full year ending March 31, 2023. For the full year, the company expects sales of JPY 45,000 million and the operating income of JPY 14,500 million and net profit of JPY 10,300 million or JPY 83.25 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
577 JPY | +0.52% | +3.04% | -50.77% |
May. 31 | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
May. 27 | Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.77% | 456M | |
+40.73% | 739B | |
+31.06% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.96% | 240B | |
+9.46% | 210B | |
-5.15% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Provides Earnings Guidance for the Full Year Ending March 31, 2023